Who We Help: DiviTum TKa is a new FDA cleared blood test that monitors cancer
Oncologists, Pharma, Biotech and others who work in clinical trials use the DiviTum test to monitor disease progression.
biovica.comCrawled Nov 17, 2026
Oncologists, Pharma, Biotech and others who work in clinical trials use the DiviTum test to monitor disease progression.
These results are highly encouraging and highlight the potential of DiviTum TKa test to evaluate treatment efficacy
Biovica initiates a clinical trial to study DiviTum TKa levels and medication dose effects in metastatic breast cancer patients in collaboration with Yale.
Biovica partners with IT Health Fusion to commercialize the DiviTum TKa assay in Italy, where 17,000 women are diagnosed with metastatic breast cancer annually.
Biovica partners with IT Health Fusion to commercialize DiviTum TKa in Italy, where 17,000 women annually receive a metastatic breast cancer diagnosis.
Biovica secures a second work order under its expanded Master Services Agreement with a leading pharmaceutical company for a new oncology program.
Biovica seeks driven individuals to join its growing team.
Amy has a PhD in Pathology from Boston University School of Medicine and a BS in Biochemistry from the University of New Hampshire.
Biovica’s Board of Directors consists of six ordinary members elected by the AGM, including Chairman of the Board.
Henrik has 20+ years of experience in the in vitro diagnostic (IVD) industry bringing biomarker assays into global clinical use and managing roles within R&D and Business Development.
Mattias has over 25 years of experience in pharma and biotech, focusing on oncology drug development and biomarker innovation.
Biovica, a Swedish biotech company, develops & commercializes novel blood-based biomarker assays. DiviTum measures cell proliferation.
Biovica holds FDA 510(k) clearance, CE marking, and ISO 13485:2016 certification.
DiviTum TKa test is a blood test that measures cell proliferation and is used as an aid in monitoring cancer progression